Interim report - Q1 2021/22
16 Marzo 2022 - 3:45AM
Interim report - Q1 2021/22
Roblon reports better-than-expected revenue and earnings
for Q1 2021/22Interim report – Q1 2021/22 (the period 1
November 2021 – 31 January 2022)
Highlights of the interim report of the Roblon
Group:
As expected, in Q1 2021/22 Roblon was adversely impacted by
challenges owing to the COVID-19 pandemic with respect to transport
and logistics, supply of raw materials and market impacts. Despite
these challenges, the Group’s reported revenue and earnings for Q1
2021/22 exceeded the guidance. The improvement was mainly driven by
growth in the US subsidiary.
As described in company announcement no. 1/2022, the Group
acquired the Czech company Vamafil spol. s.r.o at 3 January 2022. A
preliminary purchase price allocation has been made in the amount
of approximately EURm 7.3 (DKKm 54.6).
In Q1 2021/22, Roblon increased its long-term credit facilities
by DKKm 75 to support the acquisition of Vamafil and the Group’s
growth strategy. In February 2022, Roblon took out a DKKm 10
mortgage on the Company’s buildings in Gærum to further strengthen
its long-term capital resources.
The analyses of the IFRIC agenda decision on the accounting
treatment of customisation costs in a cloud computing arrangement,
as mentioned in the 2020/21 annual report, have been completed. The
conclusion is that the Group’s accounting policies will not be
affected by IFRIC’s agenda decision.
The 2021/22 full-year guidance is unchanged compared with latest
guidance.
- In Q1 2021/22, the order intake rose to
DKKm 114.8 (DKKm 91.7) and the order book at 31 January 2022 was
DKKm 116.8 (DKKm 73.8).
- Revenue amounted to DKKm 78.3 (DKKm
42.3). Both product groups, but particularly FOC, recorded
improvements compared with the year-earlier period.
- The growth margin was in line with last
year’s at 46.6% (46.6%).
- Operating profit before depreciation,
amortisation and impairment and special items (EBITDA) was DKKm 1.4
(a loss of DKKm 12.0).
- EBIT before special items was a loss of
DKKm 4.7 (a loss of DKKm 16.6).
- Special items relating to the
acquisition of Vamafil in the Czech Republic amounted to DKKm -3.1
(DKKm 0).
- Roblon’s equity at 31 January 2022
stood at DKKm 214.3 (DKKm 225.2).
- Cash flow from operations for Q1
2021/22 was a net outflow of DKKm 16.9 (an outflow of DKKm 4.6),
adversely affected by an increase of approximately DKKm 20 in
working capital.
Guidance for full year 2021/22
The guidance is subject to uncertainty due to the adverse impact
of COVID-19 in all the Group’s markets, causing supply shortages of
certain raw materials and components. The assessment is that the
war in Ukraine could give rise to additional challenges.
Roblon has ceased all sales to Russia and Belarus as a result of
the war in Ukraine. Historically, the Group has not had significant
business activities in either Russia, Belarus or Ukraine.
After Q1 2021/22, Management maintains its full-year guidance
for 2021/22 as follows:
- Revenue in the DKKm 330-370 range
(2020/21: DKKm 249.9).
- Operating profit before depreciation,
amortisation and impairment and special items (EBITDA) in the range
of DKKm 8-27 (2020/21: a loss of DKKm 12.6).
- Operating profit/loss before special
items (EBIT) in the range of a loss of DKKm 19 to a profit of DKKm
0 (2020/21: a loss of DKKm 32.9).
- Special items relating to restructuring
costs of around DKKm 8 (2020/21: DKKm 0).
Frederikshavn, 16 March 2022
Roblon A/S
Jørgen Kjær Jacobsen
Lars Østergaard
Chairman of the
Board Managing
Director and CEO
Enquiries regarding this announcement should be addressed
to:
Managing Director and CEO Lars Østergaard, tel. +45 9620
3300
- Company Announcement no 8 - 2022
Roblon A/s (LSE:0QCT)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Roblon A/s (LSE:0QCT)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024